Compare · ABCL vs NVO
ABCL vs NVO
Side-by-side comparison of AbCellera Biologics Inc. (ABCL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABCL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 58.5x ABCL ($3.68B).
- ABCL has been more active in the news (21 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 18 for ABCL).
- Company
- AbCellera Biologics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $3.68B
- $215.46B
- 1M return
- -
- -2.08%
- 1Y return
- -
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 21
- 9
- Recent ratings
- 18
- 25
AbCellera Biologics Inc.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ABCL
- Director Hayden Michael R bought $570,442 worth of shares (53,613 units at $10.64) (SEC Form 4)
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Montalbano John S. bought $110,300 worth of shares (10,000 units at $11.03), increasing direct ownership by 4% to 251,000 units (SEC Form 4)
- Chief Financial Officer Booth Andrew bought $383,904 worth of shares (37,200 units at $10.32), increasing direct ownership by 8% to 482,800 units (SEC Form 4)
- Director Hayden Michael R bought $481,033 worth of shares (46,387 units at $10.37) (SEC Form 4)
- SEC Form 8-K filed by AbCellera Biologics Inc.
- SEC Form 424B5 filed by AbCellera Biologics Inc.
- Director Hayden Michael R gifted 50,000 shares (SEC Form 4)
- AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
- SEC Form 424B5 filed by AbCellera Biologics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S